Amplia Therapeutics (Acquired) is Pharmaceuticals in Australia that focus on oncology drug candidates business. Founded in 2016. They cover business area such as developer, novel oncology drug candidate, innovative and advanced bio pharmaceutical product, Focal Adhesion Kinase, (FAK, exciting therapeutic potential, both fibrosis, immune-oncology, setting, access, cut edge product.
2016
( 8 years old in 2024 )
Oncology Drug Candidates
-
55 Flemington Road
Suite 226
North Melbourne, Victoria 3051
Australia
Private
developernovel oncology drug candidateinnovative and advanced bio pharmaceutical productFocal Adhesion Kinase(FAKexciting therapeutic potentialboth fibrosisimmune-oncologysettingaccesscut edge product
* We use standard office opening hours in near Amplia Therapeutics (Acquired)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Amplia Therapeutics (Acquired) is Pharmaceuticals business from Australia that founded in 2016 (8 years old in 2024), Amplia Therapeutics (Acquired) business is focusing on Oncology Drug Candidates.
Amplia Therapeutics (Acquired) headquarter office and corporate office address is located in 55 Flemington Road Suite 226 North Melbourne, Victoria 3051 Australia.
Amplia Therapeutics (Acquired) was founded in Australia.
In 2024, Amplia Therapeutics (Acquired) is currently focus on oncology drug candidates sector.
Above is snippet of Google Trends for "oncology drug candidates" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Amplia Therapeutics (Acquired), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
